Publication of financial results for the quarter/ year ended 31/03/2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Brawn Biotech Ltd has submitted to BSE copies of its audited standalone financial results for Q4 and full year ended 31 March 2025, which were published in Business Standard (English and Hindi) newspapers on 28 May 2025 as required under SEBI LODR Regulation 47. For Q4 FY25, total income rose to Rs 235.04 lakhs (vs Rs 165.27 lakhs in Q4 FY24), while net loss narrowed sharply to Rs 49.44 lakhs from Rs 154.42 lakhs. For full year FY25, total income stood at Rs 1,355.83 lakhs (vs Rs 1,658.27 lakhs in FY24), with a net loss of Rs 179.81 lakhs (vs Rs 154.42 lakhs loss). EPS for FY25 was Rs (5.87) vs Rs (5.14) in the previous year. The results were reviewed by the Audit Committee and approved by the Board on 26 May 2025.
The company continues to report losses, with full-year revenue declining year-on-year, which is a concern for shareholders. However, the quarterly loss narrowed significantly, suggesting some operational improvement in Q4 FY25.